Pacira BioSciences, Inc.

Drug Name	Phase	Indication	Designations	Patent
TCA IR 40	Phase 3	Osteoarthritis of the Knee	-	-
FX006	Phase 3	Osteoarthritis of the Knee	-	-
EXPAREL 67 mg	Phase 3	Postoperative Pain	-	-
ZILRETTA	Phase 3	Glenohumeral Osteoarthritis	-	-
Exparel	Phase 3	Postoperative Pain Management	-	-
Bupivacaine liposome injectable suspension 266 mg	Phase 3	Bunionectomy	-	-
bupivacaine liposome injectable suspension	Phase 3	Pain	-	-
Bupivacaine Hydrochloride	Phase 3	Lower Extremity Surgery	-	-
SKY0402	Phase 3	Hemorrhoid	-	-
Bupivacaine liposome	Phase 3	Dental Pain	-	-
EXPAREL 266 mg	Phase 3	Posterolateral Thoracotomy	-	-
Bupivacaine HCl	Phase 3	Postoperative Pain	-	-
FX006 32 mg	Phase 3	Osteoarthritis of the Shoulder	-	-
FX005	Phase 2	Osteoarthritis, Knee	-	-
TAcs 40 mg	Phase 2	Bilateral Knee Osteoarthritis	-	-
Enekinragene Inzadenovec (PCRX-201)	Phase 2	Osteoarthritis (OA) of the Knee	-	-
SKY0402 + bupivacaine HCl	Phase 2	Postoperative Pain	-	-
TCA IR 40 mg	Phase 2	Osteoarthritis of the Knee	-	-
FX006 16 mg	Phase 2	Osteoarthritis of the Knee	-	-
FX006 10 mg	Phase 2	Osteoarthritis of the Knee	-	-

Regulatory Approvals

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Pacira BioSciences, Inc.

Market Overview

PCRX News

Catalyst Timeline

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals